Follow-up Study of Short-Course Chemotherapy for Pulmonary Tuberculosis

Choi, Byoung Whui; Kim, Yong Hoon; Woo, Jun Hee; Lee, Young Hyun; Shim, Young Soo; Kim, Keun Youl; Han, Yong Chol

doi:1982.29.4.183

Tuberc Respir Dis > Volume 29(4); 1982 > Article

Original Article

Tuberculosis and Respiratory Diseases 1982;29(4):183-188.
DOI: https://doi.org/10.4046/trd.1982.29.4.183 Published online December 1, 1982.

Follow-up Study of Short-Course Chemotherapy for Pulmonary Tuberculosis

Byoung Whui Choi, Yong Hoon Kim, Jun Hee Woo, Young Hyun Lee, Young Soo Shim, Keun Youl Kim, Yong Chol Han

Department of Internal Medicine, College of Medicine, Seoul National Uniνersity, Seoul, Korea

항결핵 단기요법의 추구검사

최병휘, 김용훈, 우준희, 이영현, 심영수, 김건열, 한용철

Abstract

A clinical study was done on 381 pulmonary tuberculosis patients treated with streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ). Out of 381 patients, 197(51. 7%) have completed the prescribed duration or more of the treatment and 184 patients(48. 3%) have dropped out due to various reasons. Among 197 patients who have completed the chemotherapy, 82 patients have been treated beyond the 9 months treatment due to mainly drug resistance and retreatment. The most common cause of premature interruption was drop-out against advice. One hundred twelve patients have been followed up for more than 6 months after the termination of chemotherapy, and 86 were followed up for more than twelve months. There ￦ere no relapse at all. Among 279 patients who have been on treatment for more than one month, 58 patients (20.9%) experienced adverse reactions: 22(7.9%) changed the regimen; others unchanged. The most frequent adverse reaction was hepatotoxicity. In conclusion, SHRZ for 9 month was very effective, however, change of regimen might be necessary in case of side effect or drug-resistant case.